| Bioactivity | CPI-1189 is a TNF-α release inhibitor with antioxidant and neuroprotective properties. CPI-1189 is used for researches of HIV-associated neurotoxicity and thus is a candidate for neuroprotective therapy in humans suffered from HIV-associated CNS disease[1][2]. | |||||||||
| Name | CPI-1189 | |||||||||
| CAS | 183619-38-7 | |||||||||
| Formula | C13H18N2O2 | |||||||||
| Molar Mass | 234.29 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Müller T. CPI-1189. Centaur. Curr Opin Investig Drugs. 2002 Dec;3(12):1763-7. [2]. Clifford DB, et al. A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology. 2002 Nov 26;59(10):1568-73. |